As of 2025, retatrutide has not received MHRA or EMA marketing authorisation in the UK and remains in Phase 3 clinical trials
Although tirzepatide has been removed from the shortage list, the FDA has made it clear that they will not enforce restrictions on compounding this drug at this timeprovided that it meets their safety and quality standards
Whether youre looking to boost your energy, enhance your beauty, or improve your overall wellness, our customized IV drips can help you achieve your goals
In March 2025, she posts a detailed video about her experience with Mounjaro, hormone therapy, and Midi Health, explicitly disclosing her investment
DOI: 10.1016/j.molmet.2018.09.009 [7] Willard, F.S., Douros, J.D., Gabe, M.B., et al
Diet-Induced Models of Non-Alcoholic Fatty Liver Disease: Food for Thought on Sugar, Fat, and Cholesterol